Protease inhibitors may contribute to metabolic complications and cardiovascular risk associated with HIV infection. Here we investigate metabolic changes following treatment with darunavir/ritonavir (DRV/r)-compared with atazanavir/ritonavir (ATV/r)-based therapy.
Results 34 (median age, 37 years; men, n=29) and 31 (median age, 35 years; men, n=27) subjects were randomized to the DRV/r arm and ATV/r arm, respectively. Of these, 29 DRV/r and 25 ATV/r subjects completed Week 48. At Week 48, changes in fasting lipids and biomarkers were similar between arms. Although rates of adverse events (AEs) and laboratory abnormalities were comparable between arms, ATV/r arm had higher rates of grade 2-4 hyperbilirubinemia (n=27 [87%] vs n=1 [3%]). At Week 48, 77% of DRV/r and 71% of ATV/r subjects had VL <50 copies/mL (confirmed virologic response). Table 1 .
Conclusions
Changes from baseline to Week 48 in fasting lipids, glucose, insulin, HOMA-IR, creatinine clearance, biomarkers, CD4 and VL were similar for DRV/r and ATV/r. Given its favorable metabolic profile, which was maintained over 48 weeks, DRV/r provides a valuable therapeutic option for HIV-1-infected subjects. (22) 15 (26) 100 (24) 14 (27) IL-6, pg/mL 1.9 (1.9) 0.2 (7.3) 1.0 (1.3) 0.3 (0.9) -0.08 (-3.24, 3.08) hs-CRP, mg/L 3.1 (5.2) 1.2 (11.2) 2.2 (2.5) 0.6 (5.1) 0.65 (-4.55, 5.85) 
